Stage
Series A | AliveTotal Raised
$11MValuation
$0000Last Raised
$11M | 16 yrs agoAbout Bikam Pharmaceuticals
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Bikam Pharmaceuticals Patents
Bikam Pharmaceuticals has filed 11 patents.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Disorders of choroid and retina
- G protein coupled receptors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/29/2012 | 8/7/2018 | Diseases of the eye and adnexa, G protein coupled receptors, Vision, Ophthalmology, Transcription factors | Grant |
Application Date | 11/29/2012 |
|---|---|
Grant Date | 8/7/2018 |
Title | |
Related Topics | Diseases of the eye and adnexa, G protein coupled receptors, Vision, Ophthalmology, Transcription factors |
Status | Grant |
Bikam Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Bikam Pharmaceuticals's headquarters?
Bikam Pharmaceuticals's headquarters is located at 55 Cambridge Parkway, Cambridge.
What is Bikam Pharmaceuticals's latest funding round?
Bikam Pharmaceuticals's latest funding round is Series A.
How much did Bikam Pharmaceuticals raise?
Bikam Pharmaceuticals raised a total of $11M.
Who are the investors of Bikam Pharmaceuticals?
Investors of Bikam Pharmaceuticals include CHL Medical Partners, Fidelity Investments and Sid Martin Biotechnology Incubator.
Who are Bikam Pharmaceuticals's competitors?
Competitors of Bikam Pharmaceuticals include ChemoCentryx, Oligomerix, Sound Pharmaceuticals, Acceleron Pharma, Acumen Pharmaceuticals, Stemline Therapeutics, Portola Pharmaceuticals, Ocera Therapeutics, Threshold Pharmaceuticals, BioMarck Pharmaceuticals and 35 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Bikam Pharmaceuticals to Competitors
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.
Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.
VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
